Loading…
← CockpitCompetitor Analysis › 300558.SZ Betta Pharmaceuticals Co., Ltd. Class AOpen in the cockpit ↗

Betta Pharmaceuticals Co., Ltd. Class A300558.SZCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Major

Chinese biopharma known for icotinib (Conmana), China's first domestically developed targeted lung-cancer (EGFR inhibitor) drug.

Momentum neutral 42
Mkt cap
$2.70B
US dollars, full cap
Free float
56%
of shares outstanding
$/day
$67.1M
20-day average traded
Fwd P/E
38.0×
forward earnings
ROIC−WACC
-3.6 pp
WACC 11.2%
Hurdle
+9 pp
Req g minus delivered
Next earnings
161 days
28 Apr 2027
Close · CNYCN¥42.81
1D-1.0%
1W-8.2%
1M+2.3%
3M-37.5%
6M-15.3%
YTD-8.3%
1Y-23.4%
ATR %5.3%
52w lowhigh45.2% off high

What Betta Pharmaceuticals does

Chinese biopharma known for icotinib (Conmana), China's first domestically developed targeted lung-cancer (EGFR inhibitor) drug.

Most sales come from icotinib, sold to hospitals through distributors and reimbursed through China's state insurance list, so price negotiations, patent life and competing EGFR drugs decide the pace. Further cancer drugs are being added to reduce dependence on that single product.

Products and services

  • Icotinib (Conmana)
  • Other oncology pipeline drugs

Customers

  • Hospitals/oncologists treating lung-cancer patient

Where it sits in the supply chain

  • Health Care
  • Biopharmaceuticals
  • Targeted oncology (EGFR inhibitors)

What could go right

  • Lung-cancer targeted-therapy demand growth

What could go wrong

  • Centralized procurement price cuts
  • Competition from newer-generation EGFR drugs

Moat: narrow (IP / patents, regulatory licence). Patent-protected, first-to-market domestic EGFR-inhibitor franchise.

Headquarters: Hangzhou, China · Employees: 1,785

Named competitors

Betta Pharmaceuticals at a glance

Size Betta Pharmaceuticals (300558.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $2.70B, the 877th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥42.81 on 18 Nov 2026.

Performance Over six months the shares fell 15.3%, against -9.7% for the median peer and -20.0% for the China market (cap-weighted) — 7th lowest of 21 in its peer set.

Growth Revenue grew 16.5% over the last twelve months (peer median +2.6%); the operating margin is 11.3% (peer median 9.3%).

Valuation It trades at 38.0× forward earnings against a peer median of 24.2× (6th most expensive of 17).

Price implies For today's price to make sense, revenue must grow about 23% a year for seven years (Req g). Recent delivered growth is +14%, so the hurdle is +9 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 3.6 points below its cost of capital (11.2% WACC).

Next results Next results expected around 28 Apr 2027 (exchange calendar; dates can move).

Relative performance

8010012014021 May 202621 Aug 202618 Nov 2026Peer median 89300558.SZ 87
Six months, rebased to 100: Betta Pharmaceuticals against the median of its 20 peers (local-currency closes).

Betta Pharmaceuticals financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥3.80BCN¥3.60BCN¥2.88BCN¥2.45BCN¥2.36B
Revenue growth—+25%+18%+4%—
Gross profitCN¥3.12BCN¥2.56BCN¥2.17BCN¥1.88BCN¥1.94B
EBITDAn/aCN¥1.09BCN¥848MCN¥583MCN¥412M
Net incomeCN¥267MCN¥305MCN¥403MCN¥348MCN¥145M
Free cash flowCN¥312MCN¥296MCN¥83.6M-CN¥182M-CN¥704M
Capital expenditureCN¥550MCN¥617MCN¥828MCN¥1.10BCN¥1.01B
Total debtCN¥2.47BCN¥2.50BCN¥2.39BCN¥2.43BCN¥1.76B

Quarterly statements and history in the cockpit →

Betta Pharmaceuticals competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%-25%0%+25%+50%-20%0%300199BIOA-B600518IDYA600380301301NEULANDLAB0867ALM002773VCELPBH3696216226960013ACADNAMS000250PRGO300558.SZ6-month return →1-month return →
Up and to the right = strong over both horizons. Betta Pharmaceuticals is the large dot.

Fundamentals: revenue growth against valuation

-50%0%+50%+100%+150%25×50×75×300199BIOA-B600380301301NEULANDLAB0867ALM002773VCELPBH369626960013ACADPRGO300558.SZRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Betta Pharmaceuticals is the large dot.

Capital: growth delivered against growth the price implies

0%+50%+100%0%50%100%300199BIOA-B6003803013010867ALMVCEL36962696ACADPRGO300558.SZGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Betta Pharmaceuticals is the large dot.

Betta Pharmaceuticals competitors and peer comparison

Head to head with its named competitors (300558.SZ vs AZN.L vs 600276.SS vs 3692.HK)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Betta Pharmaceuticals 300558.SZ$2.70B-15%+16%11%38.0×23.2%
AstraZeneca AZN.L$278B-2%+5%23%17.6×14.4%
Jiangsu Hengrui Pharmaceuticals 600276.SS$45.7B-13%+6%27%33.4×13.4%
Hansoh Pharma 3692.HK$25.3B-3%+25%38%25.8×7.9%
Shanghai Allist Pharmaceuticals 688578.SS$5.32B-14%+39%47%12.4×0.1%
Roche RO.SW$381B+21%-1%31%19.9×1.7%
Innovent Biologics 1801.HK$18.9B+4%+43%17%52.3×11.6%
Sbp 1177.HK$12.2B+5%+15%30%17.5×-5.7%

How Betta Pharmaceuticals compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Betta Pharmaceuticals against its 20 peers (data as of 18 Nov 2026)
Measure300558.SZPeer medianRank in peer set
1-month return+2.3%-6.7%7th highest of 21
6-month return-15.3%-9.7%7th lowest of 21
Distance from 52-week high-45.2%-33.4%5th lowest of 21
Revenue growth (TTM)+16.5%+2.6%8th highest of 21
Operating margin11.3%9.3%10th highest of 21
Forward P/E38.0×24.2×6th most expensive of 17
Growth the price implies (Req g, 7 yrs)23.2%11.7%6th most demanding of 15
Growth delivered (Del g)+14.0%+6.8%7th highest of 15
Hurdle (Req g minus delivered)+9.2 pp-1.0 pp6th most demanding of 15
ROIC minus cost of capital-3.6 pp+0.1 pp6th lowest of 17

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Betta Pharmaceuticals 300558.SZChina$2.70B-15%+16%11%38.0×23.2%+14.0%
Hybio Pharmaceutical 300199.SZChina$2.68B-8%+70%31%44.7×37.4%+6.1%
BioArctic BIOA-B.STSweden$2.66B-9%-46%22%52.9×25.5%+100.1%
Kangmei Pharmaceutical 600518.SSChina$2.61B-21%-6%-7%n/an/an/a
IDEAYA Biosciences IDYAUnited States$2.56B-11%-83%-1,267%n/an/an/a
Joincare Pharmaceutical Group Industry 600380.SSChina$2.85B0%-12%18%15.5×-13.1%+2.4%
Yili Chuanning Biotechnology 301301.SZChina$2.49B-24%-14%16%27.6×3.4%+4.8%
Neuland Laboratories NEULANDLAB.NSIndia$2.95B+28%+50%26%63.4×n/an/a
China Medical System 0867.HKHong Kong$2.95B-15%+15%20%9.8×1.1%+2.7%
Almirall ALM.MCSpain$2.46B-13%+24%8%27.1×6.1%+6.5%
Chengdu Kanghong Pharmaceutical 002773.SZChina$2.99B-1%-11%24%20.1×-3.3%+7.0%
Vericel VCELUnited States$2.99B+66%+25%8%68.3×46.5%+17.3%
Prestige Consumer Healthcare PBHUnited States$2.40B+7%+5%25%10.6×2.3%+2.9%
InSilico Medicine Cayman TopCo 3696.HKHong Kong$2.40B-33%+153%-7%85.2×37.9%+22.9%
Keymed Biosciences 2162.HKHong Kong$2.39B+7%0%-73%18.2×n/an/a
Shanghai Henlius Biotech 2696.HKHong Kong$3.05B-39%+33%12%21.3×14.1%+61.4%
HUTCHMED (China) 0013.HKHong Kong$2.38B+14%-9%-6%35.9×47.0%+19.3%
ACADIA Pharmaceuticals ACADUnited States$3.08B-15%+15%10%17.8×9.2%+19.4%
NewAmsterdam Pharma NAMSUnited States$2.37B-45%-26%-900%n/an/an/a
Sam Chun Dang Pharm 000250.KSSouth Korea$2.36B-66%+23%7%n/an/an/a
Perrigo PRGOUnited States$2.35B+52%-4%5%6.7×14.1%+0.8%

Questions

Who are Betta Pharmaceuticals's main competitors?
Named competitors: AstraZeneca (AZN.L), Jiangsu Hengrui Pharmaceuticals (600276.SS), Hansoh Pharmaceutical (3692.HK), Allist Pharmaceuticals (688578.SS), Roche (RO.SW), Innovent Biologics (1801.HK). The cockpit's measured peer set (industry) also includes Hybio Pharmaceutical (300199.SZ), BioArctic (BIOA-B.ST), Kangmei Pharmaceutical (600518.SS), IDEAYA Biosciences (IDYA), Joincare Pharmaceutical Group Industry (600380.SS), Yili Chuanning Biotechnology (301301.SZ).
Is Betta Pharmaceuticals expensive compared with its peers?
On forward p/e it trades at 38.0× against a peer median of 24.2×, 6th most expensive of 17 in its peer set. For today's price to make sense, revenue must grow about 23% a year for seven years (Req g). Recent delivered growth is +14%, so the hurdle is +9 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Betta Pharmaceuticals stock performed?
Over six months to 18 Nov 2026 the shares returned -15.3% against -9.7% for the median peer; over one year -23.4%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.